Cell and Gene Therapy CRO

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION 
3.1. Chapter Overview 
3.2. Overview of Contract Research Organizations (CROs) 
3.2.1. Evolution of CROs 
3.2.2. Modern CROs and Prevalent Outsourcing Trends 
3.3. Type of Services Offered by CROs 
3.4. Classification of CROs 
3.5. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
3.6. Advantages of Outsourcing Operations to CROs 
3.7. Risks Associated with Outsourcing to CROs 
3.8. Future Perspectives 

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview 
4.2. Outsourcing Cell and Gene Therapy Research  
4.3. Guiding Models of Outsourcing 
4.3.1. Transactional Outsourcing Model 
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models 
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1 Key Considerations while Outsourcing Cell and Gene Therapy-related Operations
4.6. Role of CROs in Drug Development 
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Scale of Operation
5.2.5. Analysis by Area of Expertise 
5.2.6. Analysis by Preclinical Services
5.2.6.1 Analysis by Number of Preclinical Services
5.2.6.2. Analysis by Type of Preclinical Service(s) Offered
5.2.7. Analysis by Clinical Services 
5.2.7.1. Analysis by Number of Clinical Services
5.2.7.2. Analysis by Type of Clinical Service(s) Offered
5.2.8. Analysis by Type of Regulatory Service(s) Offered
5.2.9. Analysis by Type of General Support Service(s) Offered

6. COMPANY PROFILES
6.1. Chapter Overview 
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2. Allucent (Formerly Known as CATO SMS) 
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook

6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Service Portfolio
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Creative Biolabs
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook

6.2.5. IQVIA
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook

6.2.6. Medpace 
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Service Portfolio
6.2.6.4. Recent Developments and Future Outlook

6.2.7. PPD
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Service Portfolio
6.2.7.4. Recent Developments and Future Outlook

6.2.8. Precision for Medicine
6.2.8.1. Company Overview
6.2.8.2. Service Portfolio
6.2.8.3. Recent Developments and Future Outlook

6.2.9. QPS
6.2.9.1. Company Overview
6.2.9.2. Service Portfolio
6.2.9.3. Recent Developments and Future Outlook

6.3. Players based in Europe 
6.3.1. Accelera 
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook

6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook

6.3.4. Syneos Health 
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Players based in Asia-Pacific
6.4.1.1. CMIC Group
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Service Portfolio
6.4.1.5. Recent Developments and Future Outlook

6.4.2. Labcorp
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. COMPETITIVE BENCHMARKING
7.1. Chapter Overview
7.2. Assumptions and Key Methodology
7.3. Competitive Benchmarking by Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS 
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partnership and Company Size
8.3.5. Analysis by Area of Expertise
8.3.6. Analysis by Year of Partnership and Area of Expertise
8.3.7. Analysis by Type of Partnership and Area of Expertise
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Analysis by Region
8.3.9.1. Intracontinental and Intercontinental Deals
8.3.9.2. Local and International Deals

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Region
9.3.3.1. Mergers and Acquisitions: Continent-wise Distribution
9.3.3.2. Mergers and Acquisitions: Country-wise Distribution
9.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.5. Analysis by Key Value Drivers
9.3.6. Analysis by Year of Acquisition and Key Value Drivers
9.3.7. Key Acquisitions: Deal Multiples

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scoring Criteria and Key Assumptions
10.3. Scope and Methodology
10.4. Potential Strategic Acquisition Targets Amongst Small Players
10.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology
11.4. Key Potential Strategic Partners for Cell Therapy CROs
11.4.1. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.4.2. Likely Partner Opportunities for NK Cell Therapy CROs
11.4.3. Likely Partner Opportunities for Stem Cell Therapy CROs
11.4.4. Likely Partner Opportunities for T-Cell Therapy CROs

12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scoring Criteria and Key Assumptions
12.3. Scope and Methodology
12.4. Key Potential Strategic Partners for Gene Therapy CROs 
12.4.1. Likely Partner Opportunities in North America
12.4.2. Likely Partner Opportunities in Europe
12.4.3. Likely Partner Opportunities in Asia-Pacific and RoW

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Phase
13.3.4. Analysis by Type of Sponsor
13.3.5. Analysis by Geography
13.3.6. Analysis by Trial Status and Geography
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Phase
13.4.3. Analysis by Trial Status and Geography
13.5. Gene Therapies: Analysis by Number of Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Trial Phase
13.5.4. Analysis by Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Geography
13.5.7. Analysis by Trial Status and Geography
13.6. Gene Therapies: Analysis by Enrolled Patient Population
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Phase
13.6.3. Analysis by Therapeutic Area
13.6.4. Analysis by Trial Status and Geography

14. TOTAL COST OF OWNERSHIP FOR CELL AND GENE THERAPY CONTRACT RESEARCH ORGANIZATIONS
14.1 Chapter Overview
14.2. Key Parameters 
14.3. Assumptions and Methodology
14.4 Sample dataset for the estimation of total cost of ownership
14.4.1 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, Y0: Distribution of CAPEX (USD Million)
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis By OPEX, Y1-Y20

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology 
15.3. Global Cell and Gene Therapy CROs Market, 2022-2035
15.3.1. Cell and Gene Therapy CROs Market: Analysis by Area of Expertise
15.3.1.1. Cell Therapy CROs Market, 2022-2035
15.3.1.2. Gene Therapy CROs Market, 2022-2035
15.3.2. Cell and Gene Therapy CROs Market: Analysis by Scale of Operation
15.3.2.1. Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035
15.3.2.2. Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035
15.3.2.3. Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035

15.3.3. Cell and Gene Therapy CROs Market: Analysis by Therapeutic Area, 2022-2035
15.3.3.1. Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035
15.3.3.2. Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035
15.3.3.3. Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035
15.3.3.4. Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035
15.3.3.5. Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035
15.3.3.6. Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035
15.3.3.7. Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035
15.3.3.8. Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035
15.3.3.9. Cell and Gene Therapy CROs Market for Ophthalmic Disorders, 2022-2035
15.3.3.10. Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
15.3.4. Cell and Gene Therapy CROs Market: Analysis by Geography, 2022-2035
15.3.4.1. Cell and Gene Therapy CROs Market in North America, 2022-2035
15.3.4.2. Cell and Gene Therapy CROs Market in Europe, 2022-2035
15.3.4.3. Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035
15.3.4.4. Cell and Gene Therapy CROs Market in Latin America, 2022-2035
15.3.4.5. Cell and Gene Therapy CROs Market in MENA, 2022-2035

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors

17. CONCLUSION
17.1. Chapter Overview

18. INTERVIEW AND SURVEY TRANSCRIPTS
18.1. Chapter Overview
18.2. CATO SMS
18.2.1. Company Snapshot
18.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales

18.3. Changhai Hospital, Second Military Medical University
18.3.1. University Snapshot
18.3.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director, Department of Oncology

18.4. University of Colorado
18.4.1. University Snapshot
18.4.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Mergers and Acquisitions
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Stages of the Drug Development Process
Figure 3.2 Services Offered by CROs
Figure 3.3 Advantages of Outsourcing Operations to CROs
Figure 3.4 Risks Associated with Outsourcing Operations to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
Figure 4.1 Guiding Models of Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
Figure 4.4 Key Considerations while Selecting a CRO Partner
Figure 4.5 Role of CROs across Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 5.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size, and Location of Headquarters
Figure 5.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 5.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Figure 5.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Figure 5.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Figure 5.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Figure 5.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Figure 5.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Figure 5.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Figure 5.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Figure 5.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Figure 6.1 Altasciences: Service Portfolio
Figure 6.2 Allucent (Formerly known as CATO SMS): Service Portfolio
Figure 6.3 Charles River Laboratories: Annual Revenues, FY 2017-3M 2022 (USD Billion)
Figure 6.4 Charles River Laboratories: Service Portfolio
Figure 6.5 Creative Biolabs: Service Portfolio for CAR-T Therapy Development
Figure 6.6 Creative Biolabs: Service Portfolio for TCR Therapy Development
Figure 6.7 IQVIA: Annual Revenues, FY 2017-3M 2022 (USD Billion)
Figure 6.8 IQVIA: Service Portfolio
Figure 6.9 Medpace: Annual Revenues, FY 2017-3M 2022 (USD Million)
Figure 6.10 Medpace: Service Portfolio
Figure 6.11 Medpace: Regulatory Affair Capabilities
Figure 6.12 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Figure 6.13 PPD: Service Portfolio
Figure 6.14 Precision for Medicine: Service Portfolio
Figure 6.15 QPS: Service Portfolio
Figure 6.16 Accelera: Service Portfolio
Figure 6.17 Evotec: Annual Revenues, FY 2017-3M 2022 (EUR Million)
Figure 6.18 Evotec: Service Portfolio
Figure 6.19 ICON: Service Portfolio
Figure 6.20 Syneos Health: Annual Revenues, FY 2017-3M 2022 (USD Billion)
Figure 6.21 Syneos Health: Service Portfolio
Figure 6.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Figure 6.23 CMIC Group: Service Portfolio
Figure 6.24 Labcorp: Annual Revenues, FY 2017- 3M 2022 (USD Billion)
Figure 6.25 Labcorp: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 7.3 Competitive Benchmarking: Mid-Sized Players based in North America (Peer Group II)
Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 7.6 Competitive Benchmarking: Mid-Sized Players based in Europe (Peer Group V)
Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific and RoW (Peer Group VII)
Figure 7.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Area of Expertise
Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Expertise
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 8.10 Partnerships and Collaborations: Local and International Deals
Figure 9.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 9.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 9.5 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.7 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.8 Mergers and Acquisitions: Distribution by Deal Multiples Based on Revenues
Figure 13.1 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Enrolled Patient Population by Trial Registration Year
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.8 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.9 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.10 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.11 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Figure 13.12 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Figure 13.13 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Figure 13.14 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 13.15 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.16 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20 (USD Million)
Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0: Distribution of CAPEX (USD Million)
Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 15.1 Global Cell and Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.2 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Figure 15.3 Cell Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.4 Gene Therapy CROs Market, 2022-2035 (USD Million)
Figure 15.5 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Figure 15.6 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Figure 15.7 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Figure 15.8 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Figure 15.9 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Figure 15.10 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Figure 15.11 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 15.12 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 15.13 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 15.14 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 15.15 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Figure 15.16 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Figure 15.17 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Figure 15.18 Cell and Gene Therapy CROs Market for Ophthalmic Disorders, 2022-2035 (USD Million)
Figure 15.19 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035 (USD Million)
Figure 15.20 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035
Figure 15.21 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Figure 15.22 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Figure 15.23 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 15.24 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Figure 15.25 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)
Figure 16.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
Figure 17.1 Concluding Remarks: Overall Market Landscape
Figure 17.2 Concluding Remarks: Partnerships and Collaborations
Figure 17.3 Concluding Remarks: Mergers and Acquisitions
Figure 17.4 Concluding Remarks: Clinical Trial Analysis
Figure 17.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

 
 
 
Table 3.1 List of Approved ATMP Products
Table 4.1 Attributes of Transactional Outsourcing-based Business Model
Table 5.1 List of Cell and Gene Therapy CROs
Table 5.2 Cell and Gene Therapy CROs: Information on Type of Preclinical Service(s) Offered
Table 5.3 Cell and Gene Therapy CROs: Information on Type of Clinical Service(s) Offered
Table 5.4 Cell and Gene Therapy CROs: Information on Type of Regulatory Service(s) Offered
Table 5.5 Cell and Gene Therapy CROs: Information on Type of General Service(s) Offered
Table 6.1 Altasciences: Company Overview
Table 6.2 Altasciences: Recent Developments and Future Outlook
Table 6.3 Allucent (Formerly known as CATO SMS): Company Overview
Table 6.4 Allucent (Formally Known as CATO SMS): Recent Developments and Future Outlook
Table 6.5 Charles River Laboratories: Company Overview
Table 6.6 Charles River Laboratories: Recent Developments and Future Outlook
Table 6.7 Creative Biolabs: Company Overview
Table 6.8 IQVIA: Company Overview
Table 6.9 Medpace: Company Overview
Table 6.10 PPD: Company Overview
Table 6.11 PPD: Recent Developments and Future Outlook
Table 6.12 Precision for Medicine: Company Overview
Table 6.13 Precision for Medicine: Recent Developments and Future Outlook
Table 6.14 QPS: Company Overview
Table 6.15 Accelera: Company Overview
Table 6.16 Evotec: Company Overview
Table 6.17 ICON: Company Overview
Table 6.18 ICON: Recent Developments and Future Outlook
Table 6.19 Syneos Health: Company Overview
Table 6.20 Syneos Health: Recent Developments and Future Outlook
Table 6.21 CMIC Group: Company Overview
Table 6.22 CMIC Group: Recent Developments and Future Outlook
Table 6.23 Labcorp: Company Overview
Table 6.24 Labcorp: Recent Developments and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Cell and Gene Therapy CROs: List of Partnerships and Collaborations, 2015-2022
Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015-2022
Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Area of Expertise, 2015-2022
Table 9.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2022
Table 10.1 Potential Strategic Acquisition Targets Amongst Small Players
Table 10.2 Potential Strategic Acquisition Targets Amongst Mid-sized Players
Table 11.1 Likely Partners for Dendritic Cell Therapy CROs
Table 11.2 Likely Partners for NK Cell Therapy CROs
Table 11.3 Likely Partners for Stem Cell Therapy CROs
Table 11.4 Likely Partners for T-Cell Therapy CROs
Table 12.1 Likely Partner Opportunities in North America
Table 12.2 Likely Partner Opportunities in Europe
Table 12.3 Likely Partner Opportunities in Asia-Pacific and RoW
Table 13.1 Clinical Trial Analysis: Emerging Molecules
Table 13.2 Clinical Trial Analysis: Most Important Trials
Table 14.1 Total Cost of Ownership: Sample Dataset
Table 19.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Table 19.2 Cell and Gene Therapy CROs: Distribution by Company Size
Table 19.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region-wise)
Table 19.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country-wise)
Table 19.5 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 19.6 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 19.7 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Table 19.8 Cell and Gene Therapy CROs: Distribution by Scale of Operation and Area of Expertise
Table 19.9 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Table 19.10 Cell and Gene Therapy CROs: Distribution by Number of Preclinical Services
Table 19.11 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Service(s) Offered
Table 19.12 Cell and Gene Therapy CROs: Distribution by Number of Clinical Services
Table 19.13 Cell and Gene Therapy CROs: Distribution by Type of Clinical Service(s) Offered
Table 19.14 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Service(s) Offered
Table 19.15 Cell and Gene Therapy CROs: Distribution by Type of General Service(s) Offered
Table 19.16 Charles River Laboratories: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.17 IQVIA: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.18 Medpace: Annual Revenues, FY 2017-Q1 2022 (USD Million)
Table 19.19 PPD: Annual Revenues, FY 2017-9M 2021 (USD Billion)
Table 19.20 Evotec: Annual Revenues, FY 2017-Q1 2022 (EUR Million)
Table 19.21 Syneos Health: Annual Revenues, FY 2017-Q1 2022 (USD Billion)
Table 19.22 CMIC Group: Annual Revenues, 2017-H1 2022 (JPY Billion)
Table 19.23 Labcorp: Annual Revenues, FY 2017- Q1 2022 (USD Billion)
Table 19.24 Benchmark Analysis: Distribution by Location of Headquarters and Company Size
Table 19.25 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 19.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.28 Partnerships and Collaborations: Distribution by Area of Expertise
Table 19.29 Partnerships and Collaborations: Distribution by Year of Partnership and Area of Expertise
Table 19.30 Most Active Players: Distribution by Number of Partnerships
Table 19.31 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 19.32 Partnerships and Collaborations: Local and International Deals
Table 19.33 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2015-2022
Table 19.34 Mergers and Acquisitions: Distribution by Type of Agreement
Table 19.35 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 19.36 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 19.37 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.38 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.39 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 19.40 Mergers and Acquisitions: Deal Multiples Based on Revenues
Table 13.1 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 19.2 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 19.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 19.4 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Table 19.5 Clinical Trial Analysis for Cell Therapies: Geographical Distribution by Number of Registered Trials
Table 19.6 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Enrolled Patient Population by Trial Registration Year
Table 19.7 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.8 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 19.9 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 19.10 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 19.11 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Table 19.12 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Table 19.13 Clinical Trial Analysis for Gene Therapies: Geographical Distribution by Number of Registered Trials
Table 19.14 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 19.15 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Table 19.16 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Therapeutic Area
Table 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Table 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Table 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20 (USD Million)
Table 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0: Distribution of CAPEX (USD Million)
Table 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 19.79 Global Cell and Gene Therapy CROs Market 2022-2035 (USD Million)
Table 19.80 Cell and Gene Therapy CROs Market: Distribution by Area of Expertise
Table 19.81 Cell Therapy CROs Market, 2022-2035 (USD Million)
Table 19.82 Gene Therapy CROs Market, 2022-2035 (USD Million)
Table 19.83 Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
Table 19.84 Cell and Gene Therapy CROs Market for Preclinical Operations, 2022-2035 (USD Million)
Table 19.85 Cell and Gene Therapy CROs Market for Clinical Operations, 2022-2035 (USD Million)
Table 19.86 Cell and Gene Therapy CROs Market for Drug Discovery Operations, 2022-2035 (USD Million)
Table 19.87 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
Table 19.88 Cell and Gene Therapy CROs Market for Oncological Disorders, 2022-2035 (USD Million)
Table 19.89 Cell and Gene Therapy CROs Market for Neurological Disorders, 2022-2035 (USD Million)
Table 19.90 Cell and Gene Therapy CROs Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Table 19.91 Cell and Gene Therapy CROs Market for Infectious Diseases, 2022-2035 (USD Million)
Table 19.92 Cell and Gene Therapy CROs Market for Metabolic Disorders, 2022-2035 (USD Million)
Table 19.93 Cell and Gene Therapy CROs Market for Autoimmune Disorders, 2022-2035 (USD Million)
Table 19.94 Cell and Gene Therapy CROs Market for Blood Disorders, 2022-2035 (USD Million)
Table 19.95 Cell and Gene Therapy CROs Market for Rare / Genetic Disorders, 2022-2035 (USD Million)
Table 19.96 Cell and Gene Therapy CROs Market for Ophthalmic Disorders, 2022-2035 (USD Million)
Table 19.97 Cell and Gene Therapy CROs Market for Other Disorders, 2022-2035
Table 19.98 Cell and Gene Therapy CROs Market: Distribution by Geography, 2022 and 2035 (USD Million)
Table 19.99 Cell and Gene Therapy CROs Market in North America, 2022-2035 (USD Million)
Table 19.100 Cell and Gene Therapy CROs Market in Europe, 2022-2035 (USD Million)
Table 19.101 Cell and Gene Therapy CROs Market in Asia-Pacific, 2022-2035 (USD Million)
Table 19.102 Cell and Gene Therapy CROs Market in Latin America, 2022-2035 (USD Million)
Table 19.103 Cell and Gene Therapy CROs Market in MENA, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

1. 3P Biopharmaceuticals
2. 4Clinics
3. 4D Molecular Therapeutics
4. AAVantgarde Bio
5. AavantiBio
6. aaVective
7. AaviGen
8. AAVogen
9. Abeona Therapeutics
10. Absorption Systems Systems (Acquired by Pharmaron) 
11. Accelera
12. AccelLAB
13. Accelovance
14. Accord Research
15. Acer Therapeutics
16. Activartis Biotech
17. Adaptimmune Therapeutics
18. Adicet Bio
19. Adrenas Therapeutics
20. Aduro Biotech
21. Advanced BioScience Laboratories
22. Advanced Cell Diagnostics 
23. Advaxis
24. Advent Bioservices
25. Adverum Biotechnologies
26. Aevitas Therapeutics
27. Affinia Therapeutics
28. Agathos Biologics
29. AGC Biologics
30. AgenTus Therapeutics
31. AGINKO Research
32. AGTC
33. Akouos
34. Akron Biotech
35. Alia Therapeutics
36. Allele Biotechnology and Pharmaceuticals
37. Allergan (Acquired by AbbVie)
38. Allife Medical Science and Technology
39. Allogene Therapeutics
40. Allucent (Formerly known as CATO SMS)
41. Alpha Cognition
42. AlphaVax
43. Altasciences
44. Altheia Science
45. Altor BioScience
46. Amarna Therapeutics
47. Ambulero
48. American Gene Technologies
49. Amgen
50. Amphera
51. Amulet Capital Partners
52. Anaeropharma Science
53. AnGes
54. Anhui Kedgene Biotechnology
55. ANI Pharmaceuticals
56. Anjarium Biosciences
57. Ankarys Therapeutics 
58. HebeCell
59. Anlong Biopharmaceutical
60. apceth Biopharma
61. Apellis Pharmaceuticals
62. Applied StemCell
63. ARBELE 
64. Argos Therapeutics
65. Aruvant Sciences
66. ASC Therapeutics
67. Ascendance Biotechnology
68. Ascidian Therapeutics
69. Asklepios BioPharmaceutical
70. Aspa Therapeutics
71. Aspire Health Science
72. Astellas Pharma
73. Asterand Bioscience
74. Asterias Biotherapeutics
75. AstraZeneca
76. Atamyo Therapeutics
77. Atara Biotherapeutics
78. Athersys
79. Atreca
80. Atsena Therapeutics
81. Aurigon
82. Aurora Biopharma
83. Austrianova
84. Autolus
85. Avance Biosciences
86. Avance Clinical
87. Avania
88. AVAX Technologies
89. AviadoBio
90. Avrion Therapeutics
91. AVROBIO
92. Axovia Therapeutics
93. Basic Pharma
94. Baxalta
95. Baxter
96. Bayer
97. Be The Match BioTherapies
98. Beam Therapeutics
99. Beijing Biohealthcare Biotechnology
100. Beijing Doing Biomedical
101. Beijing Immunochina Medical Science & Technology
102. Beijing Sanwater Biological Technology
103. Beijing Tricision Biotherapeutics 
104. Beike Biotechnology
105. Belief BioMed
106. Bellicum Pharmaceuticals
107. Bio Elpida
108. BioAccess
109. BioAgilytix
110. BioAtla
111. BioCardia
112. BioCentriq
113. Biogen
114. Bioheng
115. Bioinova
116. Biointaxis
117. BioIVT
118. BioMarin Pharmaceutical
119. Biomere
120. BioNTech
121. BioRestorative Therapies 
122. Bio-Techne 
123. Biotect Services
124. BioVec Pharma
125. Bioville
126. bluebird bio
127. Bone Therapeutics
128. Borea Therapeutics
129. BrainStorm Cell Therapeutics
130. BridgeBio
131. Bristol-Myers Squibb
132. C3i (Center of Excellence for Cellular Therapy)
133. Caladrius Biosciences
134. Cambridge Biomedical
135. Cambridge Gene Therapy
136. Candel Therapeutics
137. Capricor Therapeutics
138. Capsida Biotherapeutics
139. Captain T Cell
140. CardioCell
141. Carina Biotech
142. CARsgen Therapeutics
143. Car-T Shanghai Biotech
144. Cartherics
145. Castle Creek Biosciences
146. Catalent Biologics
147. Catalyst Biosciences
148. Ce3
149. Celgene
150. Celixir
151. Cell and Gene Therapy Catapult
152. Cell Biotech
153. Cell Genesys
154. Cell Therapies
155. Cell-Easy
156. Cellectar Biosciences
157. Cellectis
158. Cellero (Acquired by Charles River Laboratories)
159. Cellex Cell Professionals
160. CellGenTech
161. Cellin Technologies
162. Cellmed
163. CellMP (subsidiary of Emmecell)
164. CellPraxis
165. CellProtect Biotechnology
166. CellProtect Nordic Pharmaceuticals
167. CellProthera
168. CellTrans
169. Cellular Therapeutics
170. Celonic
171. Celsion
172. Celularity
173. Celyad
174. CG Oncology
175. CHA Biolab
176. Charles River Laboratories
177. Chengdu MedGenCell
178. Chiltern
179. Chimeric Therapeutics
180. China Regenerative Medicine International
181. CiMaas
182. Citoxlab
183. City of Hope
184. Clean Cells
185. Clearside Biomedical
186. Clinical Network Services (CNS)
187. Clinscience
188. Cmed Clinical Services
189. CMIC
190. CO.DON
191. Coave Therapeutics
192. CODA Biotherapeutics
193. Code Biotherapeutics
194. Cogent Biosciences
195. Cognate BioServices
196. CoImmune
197. CombiGene
198. Comparative Biosciences
199. Cook MyoSite
200. Copernicus Therapeutics
201. Corestem
202. Covance
203. CRC Oncology
204. Creative Biolabs
205. CRISPR Therapeutics
206. Crown Bioscience
207. CSL Behring
208. CTI Clinical Trial and Consulting Services
209. Cynvec
210. Cytopeutics
211. Cytovac
212. Daiichi Sankyo
213. DanDrit Biotech
214. DCPrime
215. Decibel Therapeutics
216. Deep Science Ventures
217. Delta-Vir
218. Dendreon
219. Diamond Pharma Services (acquired by ProPharma)
220. DiNAQOR
221. DiscGenics
222. DNAlite Therapeutics
223. DNAtrix
224. Editas Medicine
225. ElevateBio
226. Eli Lilly
227. Emendo Biotherapeutics
228. Emmes
229. Encoded Therapeutics
230. Endocyte
231. Endsulin
232. enGene
233. Enochian BioSciences
234. Envigo
235. Epeius Biotechnologies
236. Ergomed
237. Eureka Therapeutics
238. Eutilex
239. Ever Union Biotechnology 
240. Evotec
241. Evox Therapeutics
242. Excelya
243. Excision BioTherapeutics
244. Exegenesis Bio
245. Experior
246. Expression Therapeutics
247. EXUMA Biotech
248. Eyevensys
249. Fast-Track Drugs and Biologics
250. Fate Therapeutics
251. FerGene (Ferring Pharmaceuticals subsidiary)
252. Ferrer Internacional
253. FGK Clinical Research
254. Fibrocell Technologies
255. Five Prime Therapeutics
256. Flash Therapeutics
257. Flexion Therapeutics
258. Forge Biologics
259. Formula Pharmaceuticals
260. Fortress Biotech
261. Fosun Kite Biotechnology
262. Freeline Therapeutics
263. Froceth
264. Frontage Laboratories
265. Gadeta
266. Gamida Cell
267. GC Cell (Previously known as Green Cross Cell)
268. Geistek Pharmaceuticals
269. GenCure (A subsidiary of BioBridge Global)
270. Gene Therapy Research Institution
271. GeneCure Biotechnologies
272. Genelux
273. GeneMedicine
274. Genenta Science
275. Genentech
276. GeneOne Life Science
277. GeneQuine Biotherapeutics
278. Generation Bio
279. Genesis Biotechnology
280. Genespire
281. Genethon
282. GeneWerk
283. Genexine
284. Genflow Biosciences
285. GenIbet Biopharmaceuticals
286. GenoSafe
287. Genprex
288. GenSight Biologics
289. Genzyme
290. GigaGen 
291. GlaxoSmithKline
292. Global Cell Med
293. Global Center for Medical Innovation
294. Glycostem Therapeutics
295. Gradalis
296. Graphite Bio
297. Green Cross
298. Green Cross LabCell
299. GRI Bio
300. Gsap
301. Guangzhou Trinomab Biotech
302. Gyroscope Therapeutics
303. Heat Biologics
304. Hebei Senlang Biotechnology
305. Helixmith
306. HemaCare
307. HemoGenix
308. Hemostemix
309. HengRui YuanZheng Bio-Technology
310. Herantis Pharma
311. Histocell
312. Histogenics
313. Holostem Terapie Avanzate
314. Homology Medicines
315. Huida (Shanghai) Biotechnology
316. Human Stem Cells Institute PJSC
317. HuMurine Technologies
318. Hunan Zhaotai Yongren Biotech
319. iCarTAB BioMed
320. iCell Gene Therapeutics
321. ICON
322. ICRC-Weyer
323. iECURE
324. Ikarovec
325. Ilya Pharma
326. Imanis Life Sciences
327. Immatics
328. Immune Therapeutics
329. Immunicum
330. ImmunoCellular Therapeutics
331. Immunocore
332. Immunovative Therapies 
333. Immutep
334. IMS Health
335. INC Research
336. IncoCell Tianjin (A subsidiary of Boyalife)
337. Incysus
338. Innovative Cellular Therapeutics
339. Inovio Pharmaceuticals
340. inRegen
341. Intas Pharmaceuticals
342. Intellia Therapeutics
343. International Stem Cell Corporation
344. Intertek Pharmaceutical Services
345. inVentiv Health
346. Iovance Biotherapeutics
347. IPM Biotech
348. IQVIA
349. ISTO Technologies
350. IVERIC bio
351. Ivy Life Sciences
352. Jaguar Gene Therapy
353. Janssen
354. Janssen Pharmaceuticals
355. Japan Tissue Engineering
356. Jeune (A subsidiary of Krystal Biotech)
357. Juno Therapeutics
358. JW Biotechnology
359. JW CreaGene
360. Kadimastem
361. Kate Therapeutics
362. KBI Biopharma
363. KCR
364. Kuopio Center for Gene and Cell Therapy 
365. Kiadis Pharma
366. Kiromic
367. Kite Pharma
368. Klinar CRO
369. Kodikaz Therapeutic Solutions
370. Kolon TissueGene
371. Kriya Therapeutics
372. Krystal Biotech
373. Kubota Vision
374. Kuur Therapeutics
375. LabCorp
376. Lacerta Therapeutics
377. LatinaBA 
378. Legend Biotech
379. Lentistem® Biotech
380. Leucid Bio
381. LEXEO Therapeutics
382. Lifecells
383. Lineage Cell Therapeutics
384. Linical
385. Linical Accelovance
386. Lion TCR
387. Living Pharma
388. LogicBio Therapeutics
389. Lokon Pharma
390. Longeveron
391. Longmore 60 Biotech
392. Lovelace Biomedical
393. Lumos Pharma
394. Lyell Immunopharma
395. Lykan Bioscience
396. Lysogene
397. Magenta Therapeutics
398. Marino Biotechnology
399. MaxCyte
400. Medelis
401. Medeor Therapeutics
402. Medidee
403. Medigene
404. MEDINET
405. Mediphage Bioceuticals
406. MEDIPOST
407. Medpace
408. MedVax Technologies
409. MeiraGTx
410. Merck Serono
411. Mesoblast
412. Metagenomi
413. MetbAxis
414. MI Bioresearch
415. Milo Biotechnology
416. Minaris Regenerative Medicine
417. Minovia Therapeutics
418. MolecuVax
419. Momotaro-Gene
420. Momotaro-Gene
421. Moraga Biotechnology
422. MPI Research
423. Multimmune
424. MultiVir
425. Mustang Bio 
426. Myosana Therapeutics
427. KAEDI Biotech
428. Nanoscope Therapeutics
429. NantKwest
430. Navega Therapeutics
431. Neopharm
432. NetValue BioConsulting
433. NeuExcell Therapeutics
434. Neuracle Genetics
435. Neuralstem
436. Neurocore
437. Neurogene
438. Neurophth Therapeutics
439. Nikon CeLL innovation
440. Ninevah Therapeutics
441. Nkarta
442. Noble Life Sciences
443. Noga Therapeutics
444. Nohla Therapeutics
445. Noile-Immune Biotech
446. Northern Therapeutics
447. Northwest Biotherapeutics
448. Novadip Biosciences
449. Novartis
450. NovaRx
451. NovaTrials
452. Novella Clinical
453. Novex Innovations
454. Novotech 
455. Nuntius Therapeutics
456. Nuo Therapeutics
457. Nuventra (Acquired by Allucent)
458. OBiO Technology
459. OhioHealth
460. OiDE BetaRevive
461. Oisin Biotechnologies
462. Ology Bioservices
463. OncoBay Clinical
464. Oncobiomed
465. Oncolys BioPharma
466. Oncorus
467. OncoSenX
468. Opexa Therapeutics
469. Opus Genetics
470. ORCA Therapeutics
471. Orchard Therapeutics
472. Osiris Therapeutics
473. Oxford BioMedica
474. Oxular
475. PathoQuest 
476. Pattern BioSciences
477. PDC*line Pharma
478. PeriphaGen
479. PersonGen BioTherapeutics
480. Pfizer
481. PharmaBio
482. Pharmahungary 
483. PharmaLex
484. Pharmaron 
485. Pharmaseed
486. Pharmicell
487. Phoenix Nest
488. PhorMed
489. Pilgrim Quality Solutions
490. Pinze Lifetechnology
491. Pique Therapeutics
492. Pluristem Therapeutics
493. Plus Therapeutics
494. Poseida Therapeutics
495. PPD
496. PRC Clinical
497. Precigen
498. Precision BioSciences
499. Precision for Medicine
500. Pregene ShenZhen Biotechnology
501. Primera Analytical Solutions
502. Promethera Biosciences
503. ProPharma
504. ProtaGene (Formerly known as  Protagen Protein Services)
505. Provia Laboratories
506. PSI CRO
507. PsiOxus Therapeutics
508. PSNResearch
509. PTC Therapeutics
510. Purespring Therapeutics
511. QbD
512. QPS
513. Q-Trials
514. Quality Assistance
515. Radyus Research
516. Redbiotec
517. Redpin Therapeutics
518. Reflection Biotechnologies
519. Regeneris Medical
520. Regeneron
521. Regeneus
522. regenold
523. REGENXBIO
524. Rejuvenate Bio
525. Remedium Bio
526. ReNeuron
527. Renova Therapeutics
528. Research Dynamics
529. Rexgenero
530. Reyon Pharmaceutical
531. RHEACELL
532. Ring Therapeutics
533. Riyadh Pharma
534. Rocket Pharmaceuticals
535. Roslin Cell Therapies
536. Rubius Therapeutics
537. S.Biomedics
538. Strategic Preclinical Product Development (S2PD)
539. SalioGen Therapeutics
540. Sana Biotechnology
541. Sangamo Therapeutics
542. Sanofi
543. Sarah Cannon Development Innovations
544. Sarepta Therapeutics
545. Saronic Biotechnology
546. SBH Sciences
547. Scancell
548. Scandinavian CRO
549. SCiAN Services
550. Sclnow Biotechnology
551. SCM Lifescience
552. Scope International
553. Seattle Genetics
554. Selecta Biosciences
555. Seneca Therapeutics
556. Sensorion
557. Sentien Biotechnologies
558. Sermes CRO
559. Sernova
560. Servier
561. Seven and Eight Biopharmaceuticals
562. Shanghai BDgene Technology
563. Shanghai Bioray Laboratory
564. Shanghai GeneChem
565. Shanghai Houchao Biotechnology
566. Shanghai iCELL Biotechnology
567. Shanghai Longyao Biotechnology
568. Shanghai Sunway Biotech
569. Shanghai Unicar-Therapy Bio-medicine Technology
570. Shenzhen BinDeBio
571. Shenzhen Hornetcorn Biotechnology
572. Shionogi
573. Sibiono GeneTech
574. SillaJen
575. Sinclair Research
576. Sinobioway Cell Therapy
577. SMS-oncology
578. SMT Bio
579. SNBL USA
580. Solid Biosciences
581. Sorrento Therapeutics
582. SOTIO
583. SparingVision
584. Spark Therapeutics
585. Spirovant Sciences
586. SpliceBio
587. SQZ Biotechnologies
588. Stem Cell Arabia
589. Stemmatters 
590. StrideBio
591. STRM.BIO
592. Sumitomo Dainippon Pharma
593. Super-T Cell Cancer Company
594. Surface Oncology
595. Svar Life Science
596. SwanBio Therapeutics
597. Symbion Research International
598. Syneos Health
599. Synteract (Acquired by Syneos Health)
600. Taconic Biosciences
601. Tactiva Therapeutics
602. Taiwan Bio Therapeutics
603. Takara Bio
604. Takeda Pharmaceutical
605. Tamid Bio
606. TapImmune 
607. Targazyme
608. Targovax
609. TC BioPharm
610. TCR2 Therapeutics
611. TCTC Group
612. TeamedOn International
613. TechnoPharmaSphere
614. Tella
615. Tenaya Therapeutics
616. Tessa Therapeutics
617. Tetraneuron
618. TFS
619. The Cell Factory (A subsidiary of Esperite)
620. The Discovery Labs Center for Breakthrough Medicines
621. TheraBiologics
622. Theradex Oncology
623. Theravectys
624. ThermoGenesis
625. Tianhe Stem Cell Biotechnologies
626. TiGenix
627. TILT Biotherapeutics
628. Tmunity Therapeutics
629. TNK Therapeutics
630. ToolGen
631. TotipotentRX
632. TRACT Therapeutics
633. TransCell Science
634. TransCure BioServices
635. Transgene
636. Translational Drug Development 
637. TreeFrog Therapeutics
638. TFS HealthScience
639. Trialbee
640. Triumvira Immunologics
641. TVAX Biomedical
642. Tyris Therapeutics
643. U.S. Stem Cell
644. UCB
645. Ultragenyx Pharmaceutical
646. uniQure Biopharma
647. Universal Cells
648. Urovant Sciences
649. Vaccinogen
650. VBL Therapeutics
651. VCN Biosciences
652. VectorY Therapeutics
653. Vericel
654. Veristat
655. VetStem Biopharma
656. ViGeneron
657. ViroMed
658. Viscofan BioEngineering
659. Vivotecnia
660. Voyager Therapeutics
661. VREX Therapeutics
662. Waisman Biomanufacturing
663. Wake Forest Innovations
664. WCCT Global
665. WCG IRB (Formerly known as WIRB)
666. West Biotherapy
667. Wissenschaftlicher Service Pharma (WiSP)
668. Wize Pharma
669. Worldwide Clinical Trials
670. Wuhan Binhui Biotechnology
671. Wuhan Sian Medical Technology
672. WuXi AppTec
673. Wyvern Pharmaceuticals
674. Xalud Therapeutics
675. Xcell Biosciences
676. Xcelthera
677. XEME Biopharma
678. XyloCor Therapeutics
679. Zelluna Immunotherapy 
680. Zimmer Biomet
681. Ziopharm Oncology